within Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA23_Sirolimus;

model Sirolimus
  extends Pharmacolibrary.Drugs.ATC.S.S01XA23;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01XA23</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sirolimus, also known as rapamycin, is a macrolide immunosuppressant drug primarily used to prevent organ transplant rejection, particularly in kidney transplant recipients. It works by inhibiting the mammalian target of rapamycin (mTOR), leading to suppression of T-cell proliferation and activity. Approved by regulatory agencies including the FDA and EMA, sirolimus is also investigated for other immunosuppressive and antiproliferative indications.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetics of oral sirolimus in adult renal transplant patients (n=31, mixed sex, mostly stable, with ongoing immunosuppressive co-medication). Population pharmacokinetic analysis; median values cited.</p><h4>References</h4><ol><li><p>Kirchner, GI, et al., &amp; Manns, MP (2004). Clinical pharmacokinetics of everolimus. <i>Clinical pharmacokinetics</i> 43(2) 83–95. DOI:<a href=\"https://doi.org/10.2165/00003088-200443020-00002\">10.2165/00003088-200443020-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14748618/\">https://pubmed.ncbi.nlm.nih.gov/14748618</a></p></li><li><p>Adams, DM, et al., &amp; Azizkhan, RG (2016). Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. <i>Pediatrics</i> 137(2) e20153257–None. DOI:<a href=\"https://doi.org/10.1542/peds.2015-3257\">10.1542/peds.2015-3257</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26783326/\">https://pubmed.ncbi.nlm.nih.gov/26783326</a></p></li><li><p>Lee, KJ, et al., &amp; Chaturvedi, RR (2015). Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial duct. <i>Circulation. Cardiovascular interventions</i> 8(5) –. DOI:<a href=\"https://doi.org/10.1161/CIRCINTERVENTIONS.114.002233\">10.1161/CIRCINTERVENTIONS.114.002233</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25940522/\">https://pubmed.ncbi.nlm.nih.gov/25940522</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Sirolimus;
